339 related articles for article (PubMed ID: 19110415)
21. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
22. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
23. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
[TBL] [Abstract][Full Text] [Related]
24. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
Balducci L; Al-Halawani H; Charu V; Tam J; Shahin S; Dreiling L; Ershler WB
Oncologist; 2007 Dec; 12(12):1416-24. PubMed ID: 18165618
[TBL] [Abstract][Full Text] [Related]
25. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.
Romieu G; Clemens M; Mahlberg R; Fargeot P; Constenla M; Schütte M; Easton V; Skacel T; Bacon P; Brugger W
Crit Rev Oncol Hematol; 2007 Oct; 64(1):64-72. PubMed ID: 17317205
[TBL] [Abstract][Full Text] [Related]
26. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
von Minckwitz G; Kümmel S; du Bois A; Eiermann W; Eidtmann H; Gerber B; Hilfrich J; Huober J; Costa SD; Jackisch C; Grasshoff ST; Vescia S; Skacel T; Loibl S; Mehta KM; Kaufmann M;
Ann Oncol; 2008 Feb; 19(2):292-8. PubMed ID: 17846019
[TBL] [Abstract][Full Text] [Related]
27. Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim.
Ng JH; Ang XY; Tan SH; Tao M; Lim ST; Chan A
Acta Haematol; 2011; 125(3):107-14. PubMed ID: 21109731
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients.
Danova M; Chiroli S; Rosti G; Doan QV
Tumori; 2009; 95(2):219-26. PubMed ID: 19579869
[TBL] [Abstract][Full Text] [Related]
30. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
[TBL] [Abstract][Full Text] [Related]
31. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
Weycker D; Hackett J; Edelsberg JS; Oster G; Glass AG
Ann Pharmacother; 2006 Mar; 40(3):402-7. PubMed ID: 16492793
[TBL] [Abstract][Full Text] [Related]
32. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R
Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371
[TBL] [Abstract][Full Text] [Related]
35. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
Ozer H; Mirtsching B; Rader M; Luedke S; Noga SJ; Ding B; Dreiling L
Oncologist; 2007 Apr; 12(4):484-94. PubMed ID: 17470691
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
37. Pegfilgrastim use during chemotherapy: current and future applications.
Wolf T; Densmore JJ
Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.
Ramsey SD; Liu Z; Boer R; Sullivan SD; Malin J; Doan QV; Dubois RW; Lyman GH
Value Health; 2009; 12(2):217-25. PubMed ID: 18673353
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
[TBL] [Abstract][Full Text] [Related]
40. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
